Tauns Laboratories
197A.TTSE STANDARDPharmaceutical
Filed as TAUNS Laboratories,Inc. (2024-09–2026-09)
Financials · Standalone
| Fiscal year ended | 2026-06 | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|---|
| Revenue | ¥14.4bn | ¥18.6bn | ¥18.4bn | ¥15.7bn | ¥17.5bn | — |
| Operating income | ¥4.2bn | ¥8.3bn | ¥8.0bn | ¥5.0bn | — | — |
| Ordinary income | ¥4.0bn | ¥8.2bn | ¥7.8bn | ¥5.0bn | ¥11.2bn | −¥54m |
| Total assets | ¥44.6bn | ¥36.5bn | ¥29.3bn | ¥18.3bn | ¥20.3bn | ¥10.3bn |
| Net assets / equity | ¥19.4bn | ¥17.4bn | ¥13.7bn | ¥8.5bn | ¥7.4bn | ¥4.7bn |
| Operating cash flow | −¥2.8bn | ¥6.8bn | ¥9.9bn | −¥3.2bn | ¥10.7bn | — |
| EPS (basic) | ¥52.28 | ¥62.07 | ¥57.74 | ¥30.35 | ¥44.81 | ¥-0.55 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-07-01 → 2025-12-31 | Half-year | 72 figures · EDINET |
| 2024-07-01 → 2024-12-31 | Half-year | 47 figures · EDINET |